Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease

Jill M. Augustine, Jeannie K Lee, Edward P Armstrong

Research output: Contribution to journalArticle

Abstract

Crohn's disease (CD) causes chronic inflammation of the gastrointestinal tract and leads to fluctuations between active disease and remission. Certolizumab pegol is one of the newer biological treatments for patients with moderate-to-severe CD. Certolizumab pegol was shown to be effective in CD patients achieving response and remission in both randomized and non-randomized studies, and is an alternative biological treatment for CD. The available data show that certolizumab pegol achieves similar therapeutic efficacy and health-related quality of life scores in CD patients as the other biological agents, but at a higher cost, if dose escalation of other biologics is not considered. Considering subcutaneous self-administration, and lower number and frequency of injections, patients may prefer certolizumab pegol over the other biological treatments.

Original languageEnglish (US)
Pages (from-to)599-609
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number5
DOIs
StatePublished - Oct 1 2014

Fingerprint

Crohn Disease
Health Care Costs
Cost-Benefit Analysis
Therapeutics
Self Administration
Biological Factors
Biological Products
Gastrointestinal Tract
Quality of Life
Certolizumab Pegol
Inflammation
Costs and Cost Analysis
Injections

Keywords

  • biologics
  • certolizumab pegol
  • Crohns disease
  • inflammatory bowel disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Medicine(all)

Cite this

@article{43255856921548c7ba3778c1b772e46b,
title = "Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease",
abstract = "Crohn's disease (CD) causes chronic inflammation of the gastrointestinal tract and leads to fluctuations between active disease and remission. Certolizumab pegol is one of the newer biological treatments for patients with moderate-to-severe CD. Certolizumab pegol was shown to be effective in CD patients achieving response and remission in both randomized and non-randomized studies, and is an alternative biological treatment for CD. The available data show that certolizumab pegol achieves similar therapeutic efficacy and health-related quality of life scores in CD patients as the other biological agents, but at a higher cost, if dose escalation of other biologics is not considered. Considering subcutaneous self-administration, and lower number and frequency of injections, patients may prefer certolizumab pegol over the other biological treatments.",
keywords = "biologics, certolizumab pegol, Crohns disease, inflammatory bowel disease",
author = "Augustine, {Jill M.} and Lee, {Jeannie K} and Armstrong, {Edward P}",
year = "2014",
month = "10",
day = "1",
doi = "10.1586/14737167.2014.957680",
language = "English (US)",
volume = "14",
pages = "599--609",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease

AU - Augustine, Jill M.

AU - Lee, Jeannie K

AU - Armstrong, Edward P

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Crohn's disease (CD) causes chronic inflammation of the gastrointestinal tract and leads to fluctuations between active disease and remission. Certolizumab pegol is one of the newer biological treatments for patients with moderate-to-severe CD. Certolizumab pegol was shown to be effective in CD patients achieving response and remission in both randomized and non-randomized studies, and is an alternative biological treatment for CD. The available data show that certolizumab pegol achieves similar therapeutic efficacy and health-related quality of life scores in CD patients as the other biological agents, but at a higher cost, if dose escalation of other biologics is not considered. Considering subcutaneous self-administration, and lower number and frequency of injections, patients may prefer certolizumab pegol over the other biological treatments.

AB - Crohn's disease (CD) causes chronic inflammation of the gastrointestinal tract and leads to fluctuations between active disease and remission. Certolizumab pegol is one of the newer biological treatments for patients with moderate-to-severe CD. Certolizumab pegol was shown to be effective in CD patients achieving response and remission in both randomized and non-randomized studies, and is an alternative biological treatment for CD. The available data show that certolizumab pegol achieves similar therapeutic efficacy and health-related quality of life scores in CD patients as the other biological agents, but at a higher cost, if dose escalation of other biologics is not considered. Considering subcutaneous self-administration, and lower number and frequency of injections, patients may prefer certolizumab pegol over the other biological treatments.

KW - biologics

KW - certolizumab pegol

KW - Crohns disease

KW - inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=84907059062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907059062&partnerID=8YFLogxK

U2 - 10.1586/14737167.2014.957680

DO - 10.1586/14737167.2014.957680

M3 - Article

C2 - 25209304

AN - SCOPUS:84907059062

VL - 14

SP - 599

EP - 609

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 5

ER -